Impact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients

NCT ID: NCT06692231

Last Updated: 2024-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-15

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if an intervention of a hospital pharmacist could help, dialysis patients managed his treatment. In a first time, the health literacy level will be assed.

The main questions it aims to answer are:

What is the impact of the clinical pharmacist intervention on the understanding level and management level of his treatment by the patient? Does the intervention of the pharmacist has an effect on the biologicals parameters of the patient? Researchers will compare a group with a pharmacist intervention VS a group without pharmacist intervention for dialysis patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Dialysis Health Literacy Level Kidney Disease, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Controle Arm

Control arm: will have no specific intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention Arm

Intervention arm: Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.

Group Type EXPERIMENTAL

Pharmacist intervention

Intervention Type BEHAVIORAL

Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacist intervention

Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years of age
* On dialysis (peritoneal dialysis, hemodialysis) for at least 3 months
* Prescription for at least 5 daily medications
* Patient who has not received any pharmaceutical consultation from a hospital pharmacist as part of his or her treatment for chronic renal failure.

Exclusion Criteria

* Patient does not speak and/or understand French
* Patient's cognitive state does not permit an interview
* Patient not autonomous in managing his or her daily medication (e.g.: patient in nursing home)
* Patient refusal
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier de Vichy

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre hospitalier de Vichy

Vichy, France, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aurélien PIRAUD

Role: CONTACT

(+33 ) 04 70 97 13 14

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aurélien PIRAUD

Role: primary

(+33) 04 70 97 13 14

Jessica PIGNARD, Doctor

Role: backup

(+33) 04.70.97.29.57

Jessica PIGNARD, Doctor

Role: backup

Romane HUET, Doctor

Role: backup

Mathilde TAMAIN, Doctor

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHV-2024-10

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Preventing Early Dialysis Starts
NCT02183987 COMPLETED NA
Symptom Management in Patients on Dialysis
NCT05515991 ACTIVE_NOT_RECRUITING NA